Browse Category

Investment Analysis News 2 December 2025 - 3 December 2025

HCA Healthcare Stock Near Record Highs: December 2025 Earnings, Forecasts and Policy Risks Explained

HCA Healthcare Stock Near Record Highs: December 2025 Earnings, Forecasts and Policy Risks Explained

HCA Healthcare, Inc. (NYSE:HCA) is ending 2025 on a powerful note. After a year of double‑digit earnings growth and upgraded guidance, HCA stock is trading just above $500 per share, close to its 52‑week high of $520 and implying a market capitalization around $117 billion. MarketBeat On November 25, the stock touched an all‑time high of $515.85, and as of December 2 it was still near $503, more than 38% above its July 2024 peak of $363.05 — a rally powered by strong results from the company’s 191‑hospital network and an aggressive capital program. Becker’s Hospital Review This article rounds
Booking Holdings (BKNG) Stock News & Forecast for December 2025: Q3 Beat, AI Tailwinds and a 20% Upside Gap

Booking Holdings (BKNG) Stock News & Forecast for December 2025: Q3 Beat, AI Tailwinds and a 20% Upside Gap

Key takeaways This article is for information and education only and is not financial advice or a recommendation to buy or sell any security. 1. How Booking Holdings stock has traded since December 2, 2025 As of the close on December 2, 2025, Booking Holdings finished the session at about $5,135.07, up 4.97% from the prior close of $4,891.81. Intraday, the stock traded between roughly $4,903 and $5,176, on heavier‑than‑usual volume. Google+1 That rally leaves BKNG: A December 2 note from StockInvest upgraded BKNG to a “Buy candidate” after the strong session, citing: StockInvest However, the same model remains cautious
Pure Storage (PSTG) Stock Soars, Then Stumbles: Q3 2026 Earnings, AI Growth Story and 2026 Forecast on December 2, 2025

Pure Storage (PSTG) Stock Soars, Then Stumbles: Q3 2026 Earnings, AI Growth Story and 2026 Forecast on December 2, 2025

Pure Storage, Inc. (NYSE: PSTG) just delivered one of the most closely watched earnings reports in the AI infrastructure space — and the market’s reaction on December 2, 2025 was a full-on roller coaster. The flash‑storage specialist reported double‑digit revenue growth, rising subscription metrics and higher guidance for fiscal 2026, but also weaker GAAP profitability, softer cash flow and an eye‑watering valuation, leaving traders sharply divided. PR Newswire+2Quiver Quantitative+2 Below is a deep dive into the latest news, forecasts and analysis as of December 2, 2025, aimed at readers following PSTG on Google News and Discover. Key Takeaways for PSTG
CrowdStrike (CRWD) Tops Q3 2026 Earnings, Lifts Outlook on AI Demand as Valuation Debate Intensifies

CrowdStrike (CRWD) Tops Q3 2026 Earnings, Lifts Outlook on AI Demand as Valuation Debate Intensifies

CrowdStrike’s latest earnings report has turned December 2, 2025 into a pivotal day for one of the market’s flagship AI‑cybersecurity stocks. After the closing bell, the company reported fiscal third‑quarter 2026 results that edged past Wall Street expectations, raised its full‑year outlook, and showcased record demand for its Falcon platform — all while investors and analysts wrestle with whether the stock’s rich valuation leaves more upside or looming downside. Q3 2026: Revenue, Earnings and ARR Beat Expectations For the quarter ended October 31, 2025, CrowdStrike reported: On a GAAP basis, CrowdStrike is still losing money: On an adjusted (non‑GAAP) basis,
Regeneron (REGN) Stock on December 2, 2025: Outlook, Forecast and Key Catalysts After Gene‑Editing Deal

Regeneron (REGN) Stock on December 2, 2025: Outlook, Forecast and Key Catalysts After Gene‑Editing Deal

Regeneron stock snapshot on 2 December 2025 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is trading around $742 per share in late U.S. trading on December 2, 2025, after moving between roughly $731 and $749 during the session and opening close to $742. StockAnalysis Key valuation and trading metrics: Over the past month, REGN has rallied sharply. Zacks notes the stock has gained about 21.5% in a month, while a fresh Simply Wall St piece highlights a 15.1% 30‑day return and 33% gain over 90 days, framing a powerful rebound from earlier weakness. Zacks+1 Today’s headline drivers: gene‑editing deal and the Eylea
Super Micro Computer (SMCI) Stock in December 2025: Can the AI Server Star Rebound After a Brutal Sell‑Off?

Super Micro Computer (SMCI) Stock in December 2025: Can the AI Server Star Rebound After a Brutal Sell‑Off?

Updated: December 2, 2025 Key Takeaways SMCI Stock Today: Price, Valuation and Volatility As of the close on December 2, 2025, Super Micro Computer, Inc. (Supermicro, ticker SMCI) trades around $32.9 per share, with an intraday range near $32.57–$34.33. The stock’s 52‑week range is roughly $25.71–$66.44, putting today’s quote closer to the low end. At this level, the company carries a market capitalization of about $19.6 billion and trades at a trailing P/E of ~26.6x. Google November was painful: a MarketWatch review of major tech names shows Supermicro as the worst‑performing tech stock in November 2025, down about 36.8% for
Amgen (AMGN) Stock Today: Earnings Momentum, Obesity Breakthroughs and Fresh December 2, 2025 Forecasts

Amgen (AMGN) Stock Today: Earnings Momentum, Obesity Breakthroughs and Fresh December 2, 2025 Forecasts

Published: December 2, 2025 – For informational purposes only, not investment advice. Key Takeaways Amgen stock is trading around $338.67, slightly higher on the day and still near 52‑week highs after a strong run in 2025. Q3 2025 results beat expectations, with revenue up 12% to $9.6 billion and non‑GAAP EPS comfortably ahead of consensus, prompting a guidance raise for full‑year 2025.AlphaSense+1 Today, December 2, 2025, brought multiple fresh headlines: several institutional investors trimmed AMGN positions, while technical analysts flagged a short‑term bullish setup with support near $330 and resistance around $355.MarketBeat+2MarketBeat+2 Pipeline catalysts are accelerating: Once‑monthly obesity drug MariTide
AbbVie (ABBV) Stock on December 2, 2025: Dividend Hike, Cancer Pipeline Momentum and 2026 Outlook

AbbVie (ABBV) Stock on December 2, 2025: Dividend Hike, Cancer Pipeline Momentum and 2026 Outlook

AbbVie Inc. (NYSE: ABBV) heads into the final month of 2025 as one of the most closely watched large‑cap healthcare stocks, with fresh dividend news, new oncology and migraine data, and an upbeat earnings outlook all hitting the tape just as investors look toward 2026. As of December 2, 2025, AbbVie shares trade around $224–$225 per share, giving the company a market capitalization in the high‑$300 to roughly $400 billion range.TS2 Tech The stock is up roughly 20–30% in 2025, depending on the exact start date used, handily outpacing much of the broader healthcare sector.Barchart.com+2Benzinga+2 Below is a deep dive
Datadog (DDOG) Stock Today: AI Agent Launch, Q3 Earnings Momentum and Wall Street Forecasts — 2 December 2025

Datadog (DDOG) Stock Today: AI Agent Launch, Q3 Earnings Momentum and Wall Street Forecasts — 2 December 2025

Datadog, Inc. (NASDAQ: DDOG) is back in the spotlight on December 2, 2025, as the observability and security platform rolls out a major AI product, meets investors at a key technology conference and continues to digest a powerful Q3 earnings beat. As of midday trading, Datadog shares change hands around $156.5, down slightly on the session, with recent data putting the market capitalization near $56 billion and the stock still trading at a premium valuation relative to current earnings. StockAnalysis+2MarketBeat+2 Below is a detailed look at today’s news, fresh forecasts and the latest analysis driving Datadog’s stock narrative. 1. Datadog
Lam Research (LRCX) Jumps on Morgan Stanley Upgrade: Is the AI Wafer-Equipment Rally Running Hot or Just Getting Started?

Lam Research (LRCX) Jumps on Morgan Stanley Upgrade: Is the AI Wafer-Equipment Rally Running Hot or Just Getting Started?

As of Tuesday, December 2, 2025, Lam Research Corporation (NASDAQ: LRCX) is back in the market spotlight. The semiconductor equipment maker’s stock climbed to around $157–$158 per share in afternoon trading, up roughly 2% on the day after Morgan Stanley raised its price target from $137 to $158 while keeping an “Equal-Weight” rating.GuruFocus+1 That move caps a spectacular year: various data providers show Lam up well over 100% year-to-date, with MarketScreener estimating a gain of about 119% and Finviz/StockStory noting a roughly 116% rise and a share price near its 52-week high around $167.MarketScreener+1 At the same time, short interest
Vertiv Stock (VRT) in December 2025: AI Data Center Deals, Q3 Beat and Fresh Wall Street Targets

Vertiv Stock (VRT) in December 2025: AI Data Center Deals, Q3 Beat and Fresh Wall Street Targets

Vertiv Holdings Co (NYSE: VRT) has become one of Wall Street’s favorite “picks-and-shovels” plays on the AI data center boom – and the news flow around the stock has been intense going into December 2, 2025. As of late trading on December 2, 2025, Vertiv shares change hands around $183, giving the company a market capitalization of roughly $68.5 billion. The stock has traded between $53.60 and $202.45 over the past 52 weeks and currently carries a forward-looking P/E of about 68 and a PEG ratio near 1.46, underscoring how richly investors are willing to pay for its AI growth
Qualcomm Stock (QCOM) Today: AI Pivot, Apple Risk and 2025–2026 Forecast After Fresh Institutional Moves

Qualcomm Stock (QCOM) Today: AI Pivot, Apple Risk and 2025–2026 Forecast After Fresh Institutional Moves

Published: December 2, 2025 – Data and prices as of today’s close or latest available figures. Qualcomm stock today: price, valuation and sector backdrop Qualcomm Incorporated (NASDAQ: QCOM) is trading around $168 per share on December 2, 2025, after a choppy two‑week stretch that left the stock roughly 3–4% below its mid‑November levels. Intraday on Monday the shares moved between about $165.50 and $169.03, with volume around 6–7 million shares, roughly in line with recent averages. Intellectia+1 At this price, Qualcomm’s valuation looks split between an expensive past and a cheaper future: For context, the broader U.S. semiconductor industry trades
1 224 225 226 227 228 282

Stock Market Today

Meta stock faces an AI split: ad gains vs a $135 billion bill

Meta stock faces an AI split: ad gains vs a $135 billion bill

7 February 2026
Meta shares dropped 1.3% to $661.46 on Friday after the company projected 2026 capital spending of up to $135 billion, raising investor concerns over cash flow. Meta reported Q4 revenue of $59.89 billion, up 24% year-over-year, with ad impressions rising 18%. Analysts remain divided on whether AI-driven ad gains can offset the steep spending ramp.
Go toTop